For example, the gain of a MYB binding site in a random genomic position may not lead to de novo enhancer activity, whereas such a gain in the context of RUNX binding sites (MYB and RUNX bind together to leukemia enhancers) may cause ectopic enhancer activity [16]. Here, MYB is linked to leukemia.